Acquisition-driven Position integration opportunities with Johnson & Johnson post-acquisition to accelerate Arkuda’s ongoing programs and leverage J&J's clinical development resources, manufacturing capabilities, and global commercialization reach.

Strategic partnerships Offer collaborations with contract development and manufacturing organizations (CDMOs), neurodegenerative-focused biotech funds, and large pharma seeking access to Arkuda’s lysosomal biology expertise and progranulin-targeted approaches.

Early-stage programs Identify opportunities with CROs and translational research labs to support early discovery and preclinical work around frontotemporal dementia and GRN-related neurodegenerative targets, given Arkuda’s focus and prior financing signals.

Funding leverage Highlight available capital and potential for co-development deals leveraging Arkuda’s $108M funding backdrop to de-risk partnerships, milestone-driven collaborations, and potential milestone-rich financing with pharma partners.

Strategic messaging Tailor outreach around Arkuda’s niche expertise in lysosomal biology and progranulin pathways to attract investors, strategic buyers, or collaboration partners seeking differentiated neurodegeneration programs with clear translational potential.